Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Edison Pharmaceuticals patents

Patents where

Current Assignee

Name

Edison Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9169196 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases	Patent 9169196 was granted and assigned to Edison Pharmaceuticals on October, 2015 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	9169196	October 27, 2015
‌ US Patent 9162957 Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols	Patent 9162957 was granted and assigned to Edison Pharmaceuticals on October, 2015 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	9162957	October 20, 2015
‌ US Patent 9447006 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers	Patent 9447006 was granted and assigned to Edison Pharmaceuticals on September, 2016 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	9447006	September 20, 2016
‌ US Patent 9486435 (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases	Patent 9486435 was granted and assigned to Edison Pharmaceuticals on November, 2016 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	9486435	November 8, 2016
‌ US Patent 8952071 (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases	Patent 8952071 was granted and assigned to Edison Pharmaceuticals on February, 2015 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	8952071	February 10, 2015
‌ US Patent 9278085 Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers	Patent 9278085 was granted and assigned to Edison Pharmaceuticals on March, 2016 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	9278085	March 8, 2016
‌ US Patent 8653144 Treatment of pervasive developmental disorders with redox-active therapeutics	Patent 8653144 was granted and assigned to Edison Pharmaceuticals on February, 2014 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	8653144	February 18, 2014
‌ US Patent 9399612 Treatment of pervasive developmental disorders with redox-active therapeutics	Patent 9399612 was granted and assigned to Edison Pharmaceuticals on July, 2016 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	9399612	July 26, 2016
‌ US Patent 8716527 2-substituted-	Patent 8716527 was granted and assigned to Edison Pharmaceuticals on May, 2014 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	8716527	May 6, 2014
‌ US Patent 8969420 Treatment of pervasive developmental disorders with redox-active therapeutics	Patent 8969420 was granted and assigned to Edison Pharmaceuticals on March, 2015 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	8969420	March 3, 2015
‌ US Patent 8716486 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases	Patent 8716486 was granted and assigned to Edison Pharmaceuticals on May, 2014 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	8716486	May 6, 2014
‌ US Patent 8106223 Process for the production of alpha-tocotrienol and derivatives	Patent 8106223 was granted and assigned to Edison Pharmaceuticals on January, 2012 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	8106223	January 31, 2012
‌ US Patent 9370496 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones	Patent 9370496 was granted and assigned to Edison Pharmaceuticals on June, 2016 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	9370496	June 21, 2016
‌ US Patent 8791155 Chroman derivatives	Patent 8791155 was granted and assigned to Edison Pharmaceuticals on July, 2014 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	8791155	July 29, 2014
‌ US Patent 8314153 Treatment of pervasive developmental disorders with redox-active therapeutics	Patent 8314153 was granted and assigned to Edison Pharmaceuticals on November, 2012 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	8314153	November 20, 2012
‌ US Patent 9073873 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases	Patent 9073873 was granted and assigned to Edison Pharmaceuticals on July, 2015 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	9073873	July 7, 2015
‌ US Patent 9296712 Resorufin derivatives for treatment of oxidative stress disorders	Patent 9296712 was granted and assigned to Edison Pharmaceuticals on March, 2016 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	9296712	March 29, 2016
‌ US Patent 9464016 Catechol derivatives for treatment of oxidative stress diseases	Patent 9464016 was granted and assigned to Edison Pharmaceuticals on October, 2016 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	9464016	October 11, 2016
‌ US Patent 9090576 2-substituted-	Patent 9090576 was granted and assigned to Edison Pharmaceuticals on July, 2015 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	9090576	July 28, 2015
‌ US Patent 9567279 Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols	Patent 9567279 was granted and assigned to Edison Pharmaceuticals on February, 2017 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	9567279	February 14, 2017
‌ US Patent 8575369 Process for the production of alpha-tocotrienol and derivatives	Patent 8575369 was granted and assigned to Edison Pharmaceuticals on November, 2013 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	8575369	November 5, 2013
‌ US Patent 9546132 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases	Patent 9546132 was granted and assigned to Edison Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	Edison Pharmaceuticals	Edison Pharmaceuticals	United States Patent and Trademark Office	9546132	January 17, 2017
‌ US Patent 8519001 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases	Patent 8519001 was granted and assigned to Edison Pharmaceuticals on August, 2013 by the United States Patent and Trademark Office.		Edison Pharmaceuticals	United States Patent and Trademark Office	8519001	August 27, 2013

23 results

0 selected

23 results

0 selected